Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
341-360 of 998 trials

Statin Intolerance: Personalized Treatment Study

We are exploring whether personalized treatment plans can help people who struggle with statin medications. The goal is to improve their cholesterol management while minimizing side effects.

High Cardiovascular RiskStatin Intolerance6-12 monthsMonitoring phase (IV)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Basal Cell Carcinomas: Patidegib Gel 2%

We are studying a new gel for adults with Gorlin syndrome to see if it helps prevent basal cell carcinomas on the face. The trial will also check how safe and tolerable the gel is for patients.

Gorlin Syndrome1-2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyHematology

Advanced Solid Tumors: MDNA11 and Pembrolizumab Study

We are investigating the safety and effectiveness of MDNA11, given alone or with pembrolizumab, in patients with advanced solid tumors. This study aims to find the best dose and understand how the treatment works.

Solid TumorSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Myasthenia Gravis: NMD670 Treatment Study

We are testing different doses of NMD670 in adults with Myasthenia Gravis to see if it improves muscle strength. This study will help us understand how effective the treatment is compared to a placebo.

Myasthenia Gravis≤3 monthsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Membranous Nephropathy: Dapagliflozin Treatment Study

We are investigating how dapagliflozin affects immune activity and kidney function in patients with Membranous Nephropathy. This study may help us understand its potential benefits for managing this condition.

Membranous Nephropathy1-2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteInternal MedicineNephrology

Myotonic Dystrophy Type I: Metformin Study

We are investigating whether metformin can improve muscle and overall function in patients with Myotonic Dystrophy Type I. The study will also assess the safety of metformin and its effects on quality of life.

Myotonic Dystrophy Type 1 (DM1)>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology

Inclusion Body Myositis: Ruxolitinib Treatment Study

We are investigating whether ruxolitinib can improve movement and muscle function in patients with Inclusion Body Myositis. The study also looks at safety and quality of life for participants.

Inclusion Body Myositis>2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyRheumatology

Hepatocellular Carcinoma: Durvalumab and Bevacizumab Study

We are studying whether the combination of durvalumab and bevacizumab can help prevent cancer recurrence in patients with hepatocellular carcinoma after surgery or ablation. This trial compares these treatments to a placebo to assess their effectiveness.

Early Stage Liver Cancer>2 yearsConfirmation phase (III)Standard MedicinesPartially RemoteHepatologyOncology

Chronic Lymphocytic Leukemia: Pirtobrutinib vs. Ibrutinib

We are comparing the effectiveness of pirtobrutinib to ibrutinib in patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. This study also focuses on those who are newly diagnosed and have a specific genetic change.

Chronic Lymphocytic Leukemia6-12 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Hemophilia A: Long-Term Follow-Up of BMN 270

We are investigating the long-term safety and effects of a gene therapy for severe hemophilia A in individuals who participated in a previous study. This includes looking at their quality of life and the need for additional treatments.

Hemophilia A>2 yearsMonitoring phase (IV)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematology

Coronary Artery Spasm: Testing Bosentan

We are studying whether the medication bosentan can help reduce coronary artery spasms in patients with ongoing angina symptoms. The trial also aims to evaluate its effects on quality of life and safety.

Coronary Vasospasm≤3 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

iTTP Treatment: TAK-755 Study

We are testing a new treatment called TAK-755 for patients with immune-mediated thrombotic thrombocytopenic purpura. The study aims to see if it is safe and effective in reducing symptoms and preventing future episodes.

Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP)≤3 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematology

Pulmonary Embolism: Surveillance vs. Anticoagulation

We are studying whether monitoring without blood thinners is as safe and effective as using them for low-risk patients with isolated subsegmental pulmonary embolism. This trial will also assess side effects and quality of life for participants.

Isolated Subsegmental Pulmonary Embolism3-6 monthsMonitoring phase (IV)≤5 visitsStandard MedicinesPartially RemoteCardiologyPulmonology

Linvoseltamab for Relapsed or Refractory AL Amyloidosis

We are studying whether linvoseltamab is safe and effective for adults with relapsed or refractory systemic light chain amyloidosis. The trial will help us understand its impact on blood response and overall health.

Relapsed or Refractory Systemic Light Chain Amyloidosis>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyInternal Medicine

Pancreatic Exocrine Insufficiency: Creon® Therapy Study

We are exploring how Creon® may help improve nutrition and quality of life for patients with pancreatic exocrine insufficiency after total gastrectomy. The study also looks at weight changes and gastrointestinal symptoms.

Pancreatic Exocrine Insufficiency1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Cannabidiol for Refractory Childhood Epilepsy

We are studying whether adding CBD can help children with hard-to-treat epilepsy manage their seizures better. The trial also looks at how this treatment affects the quality of life for patients and their families.

Refractory Epilepsy1-2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Immunoglobulin A Nephropathy: Ravulizumab Study

We are testing whether ravulizumab can help preserve kidney function in adults with immunoglobulin A nephropathy. The study will also assess safety and quality of life compared to a placebo.

Immunoglobulin A Nephropathy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNephrology

Ulcerative Colitis: Eltrekibart Treatment Study

We are studying whether eltrekibart can help adults with moderately to severely active ulcerative colitis achieve remission. This trial compares the effects of eltrekibart to a placebo.

Ulcerative Colitis1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Multiple Myeloma: Elranatamab vs. Standard Treatments

We are studying a new treatment called elranatamab for people with relapsed refractory multiple myeloma. The goal is to see how well it works compared to current therapies and to assess its safety and impact on quality of life.

Relapsed/Refractory Multiple MyelomaConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Self-Administration of Elranatamab for Multiple Myeloma

We are exploring whether patients with multiple myeloma can safely administer Elranatamab at home. The study will assess the feasibility, safety, and impact on quality of life for both patients and their caregivers.

Multiple Myeloma1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHematologyOncology